Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Abstract
Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
Funding Information
  • AbbVie
  • Genentech

This publication has 26 references indexed in Scilit: